Ennature Bio Pharma Limited Lists on NSE, BSE November 4

Ennature Bio Pharma Limited listed on the National Stock Exchange of India and the Bombay Stock Exchange on November 4, 2026, with the NSE recent-listing record showing the symbol ENNATURE and a company page displaying a ₹10.00 close at 12:00 am IST.

When did Ennature Bio Pharma list on the exchanges?

Ennature Bio Pharma listed on November 4, 2026, according to the NSE India recent-listing record and the company information page. The NSE record identifies the security as equity shares under the symbol ENNATURE, with the BE series and ISIN INE2WCT01016.

The supplied listing information also identifies BSE code 545012 and states that the company is listed on the National Stock Exchange of India Ltd. and The Stock Exchange, Mumbai. This establishes the company as available for trading on both exchanges, although the source does not provide issue size, allotment details, offer price, or the number of shares listed.

The listing is relevant because it gives investors an exchange-traded route to buy and sell the company’s equity. However, the available material is primarily listing-page data and does not include a prospectus, financial statements, management commentary, or a stated business strategy.

What do the exchange records say about the security?

The exchange record classifies Ennature Bio Pharma as an equity security in the BE series, with ISIN INE2WCT01016. The company is shown in the “Others” or miscellaneous classification, while one listing-information page identifies the sector as General.

The available company profile data describes Ennature Bio Pharma as a small-cap company and names its parent organisation as Indian Private. Another profile entry says the company was founded in 2021. These classifications provide basic reference points, but the supplied material does not disclose revenue, profit, debt, share capital, promoter holding, or market capitalisation.

Several listing fields remain incomplete in the source material. The face value is displayed as “.0”, the market lot is shown as 0, and incorporation, public issue, book-closure, and annual general meeting date fields do not contain usable values. Investors should treat such blank or incomplete fields as unavailable information rather than as financial or operational disclosures.

Why does the reported ₹10 price require context?

The NSE-linked company information in the supplied data states that Ennature Bio Pharma’s share price stood at ₹10.00 as of November 4, 2026, at 12:00 am IST, described as the market close. The same material lists the intraday high and low as undefined, so it does not provide a usable trading range for the day.

A separate market-data extract from Angel One displays a price of ₹251.70 for Ennature Bio Pharma, while another extracted line reports ₹251.70 with a decline of ₹413.35, or 62.15%. The provided text does not specify the timestamp, trading date, or calculation basis for these figures. It therefore cannot establish whether the ₹251.70 data refers to the listing session, a later session, or a different data update.

The difference between the ₹10.00 and ₹251.70 displayed figures is material. Based solely on the provided records, investors should not use either number to calculate listing gains, returns, or valuation without checking the live exchange quote, the relevant date, and official corporate filings.

How does the listing affect investors and market participants?

The listing allows market participants to identify the security using ENNATURE on NSE and BSE code 545012 on BSE. The ISIN provides a common security identifier across market records and depository-related references, helping investors distinguish the shares from similarly named entities.

For retail investors, the BE series classification is an important operational detail to verify through their broker. The source does not explain the applicable settlement or trading conditions, and investors should rely on current exchange and broker notices for transaction rules, margin requirements, and available order types.

The available information does not show trading volume, bid and offer prices, open price, previous close, or 52-week price range. Without those measures, the supplied material does not support conclusions about liquidity, demand, price discovery, or the company’s market value after listing.

What background is available on Ennature Bio Pharma?

The supplied background pages consistently identify the company as Ennature Bio Pharma and link it to ISIN INE2WCT01016. The company is categorised under Others, with a General sector label on one page and a miscellaneous industry label on another.

The information also includes links or headings for quarterly results, nine-month results, annual results, cash flow, balance sheet, director reports, peer comparison, and IPO information. But no underlying financial figures or corporate disclosures are included in the supplied text. As a result, there is no verified basis here to assess earnings quality, cash generation, competitive position, or balance-sheet strength.

Conclusion

Ennature Bio Pharma entered the listed market on November 4, 2026, under NSE symbol ENNATURE and BSE code 545012. The records confirm the listing date, equity classification, BE series, and ISIN, while an NSE-linked page displayed a ₹10.00 close. A separate ₹251.70 price extract has no clear timestamp in the material and should not be treated as directly comparable.

The immediate point to watch is whether the exchange and company pages provide complete listing fields, including face value, market lot, trading data, and official financial disclosures. Investors can also monitor subsequent exchange quotes and company filings, as the supplied source does not disclose a forward plan, target, scheduled corporate event, or detailed IPO terms.